Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Increases speed to market for drug developers working on nucleic acid therapeutics
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
New research labs and process development services to enable next generation therapeutics
Modernization and supply chain diversity drive new growth
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Subscribe To Our Newsletter & Stay Updated